BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Holdings Lifted by XTX Topco Ltd

Key Points

• XTX Topco Ltd significantly increased its holdings in BioCryst Pharmaceuticals by 314.8%, purchasing an additional 66,320 shares, bringing its total to 87,389 shares valued at $655,000.
• Multiple institutional investors have also adjusted their positions in BioCryst Pharmaceuticals, with 85.88% of the stock currently owned by institutional investors.
• BioCryst Pharmaceuticals recently reported better-than-expected earnings with an EPS of $0.15, surpassing estimates and showing a year-over-year revenue increase of 49.5%.

XTX Topco Ltd raised its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 314.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 87,389 shares of the biotechnology company's stock after purchasing an additional 66,320 shares during the quarter. XTX Topco Ltd's holdings in BioCryst Pharmaceuticals were worth $655,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Caligan Partners LP increased its holdings in BioCryst Pharmaceuticals by 16.0% in the fourth quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock valued at $22,529,000 after buying an additional 412,347 shares during the last quarter. Two Sigma Advisers LP increased its holdings in BioCryst Pharmaceuticals by 14.6% in the fourth quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company's stock valued at $18,799,000 after buying an additional 318,800 shares during the last quarter. Northern Trust Corp boosted its stake in BioCryst Pharmaceuticals by 7.7% in the fourth quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company's stock valued at $15,077,000 after acquiring an additional 143,986 shares during the period. Eversept Partners LP boosted its stake in BioCryst Pharmaceuticals by 269.9% in the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock valued at $14,892,000 after acquiring an additional 1,444,907 shares during the period. Finally, Two Sigma Investments LP boosted its stake in BioCryst Pharmaceuticals by 0.8% in the fourth quarter. Two Sigma Investments LP now owns 1,774,214 shares of the biotechnology company's stock valued at $13,342,000 after acquiring an additional 13,406 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on BCRX shares. Needham & Company LLC restated a "buy" rating and issued a $17.00 target price on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. Royal Bank Of Canada reiterated an "outperform" rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Bank of America boosted their price objective on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Tuesday, July 1st. JPMorgan Chase & Co. boosted their price objective on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Finally, HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $16.70.

BioCryst Pharmaceuticals Trading Down 0.6%

NASDAQ:BCRX traded down $0.05 during midday trading on Friday, hitting $8.30. 1,823,000 shares of the stock were exchanged, compared to its average volume of 3,745,884. BioCryst Pharmaceuticals, Inc. has a one year low of $6.01 and a one year high of $11.31. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -46.11, a P/E/G ratio of 1.90 and a beta of 1.10. The business has a 50-day moving average price of $9.32 and a two-hundred day moving average price of $8.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. During the same period in the previous year, the firm earned ($0.06) EPS. BioCryst Pharmaceuticals's revenue for the quarter was up 49.5% on a year-over-year basis. Sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.